Vedolizumab (Entyvio®) (mAb-based)

The drug Vedolizumab (trade name Entyvio®) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7. Identification of biomarkers might be beneficial for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective concentration in order to potentially avoid some side effects with a reliable method. The specificity of this testsystem is achieved by using a monoclonal antibody named "IG-19F3" for the coating of the microtiter plate. This antibody is specific for Vedolizumab only and does not cross react with other lymphocyte integrin α4β7 catchers. Enzyme immunoassay for the specific determination of free Vedolizumab in serum and plasma. For research use only - not for use in diagnostic procedures.
List Price: $882
  • Buy 5 for $837.9 each and save 5%
  • Buy 21 for $793.8 each and save 10%
  • Buy 31 for $749.7 each and save 15%
  • Buy 51 for

Properties

Protocol PDF Click for Protocol
Catalog Number TK01745
Species Human
Design Enzyme immunoassay (ELISA) technique.
Standards 5 standards, ready to use.
Controls None provided.
Sample Types Serum and plasma.
Sample Volume 10 µL
Assay Desc. 1 hour incubation (RT) + 30 min. (RT) + 20 min. (RT) = 1 hour, 50 min. total incubation time.
Standard Range 0 / 6 - 200 ng/mL
Sensitivity 5 ng/mL
Radioactivity
Other Names Entyvio®
Storage 2 - 8°C
Postscript For research use only, not for use in diagnostic procedures.

Intended use

This ELISA kit applies to the in vitro quantitative determination of Vedolizumab (Entyvio®) (mAb-based) concentrations in serum, plasma and other biological fluids.

Test principle

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antigen specific to Vedolizumab (Entyvio®) (mAb-based). Standards or samples are added to the micro ELISA plate wells and combined with the specific antigen. Then a biotinylated detection antigen specific for Vedolizumab (Entyvio®) (mAb-based) and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Vedolizumab (Entyvio®) (mAb-based), biotinylated detection antigen and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Vedolizumab (Entyvio®) (mAb-based). You can calculate the concentration of Vedolizumab (Entyvio®) (mAb-based) in the samples by comparing the OD of the samples to the standard curve.

Typical data

As the OD values of the standard curve may vary according to the conditions of the actual assay performance (e.g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.

Precision

Intra-assay Precision (Precision within an assay):
3 samples with low, middle,high concentration of Vedolizumab (Entyvio®) (mAb-based). And the sample of Vedolizumab (Entyvio®) (mAb-based) were tested 30 times on one plate, respectively.
Inter-assay Precision (Precision between assays):
3 samples with low, middle,high concentration of Vedolizumab (Entyvio®) (mAb-based). And the sample of Vedolizumab (Entyvio®) (mAb-based) were tested on 3 different plates, 30 replicates in each plate.

Recovery

Matrices listed below were spiked with certain level of Vedolizumab (Entyvio®) (mAb-based) and the recovery rates were calculated by comparing the measured value to the expected amount of Vedolizumab (Entyvio®) (mAb-based) in samples.

Matrix Recovery range (%) Average Recovery (%)
Serum (n=5) 90-106 98
EDTA plasma (n=5) 88-97 96
heparin plasma (n=5) 91-96 93

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vedolizumab (Entyvio®) (mAb-based) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

    Serum (n=5) EDTA plasma (n=5) heparin plasma (n=5)
1:2 Range (%) 91-107 92-106 88-107
Average (%) 95 94 95
1:4 Range (%) 92-101 87-102 94-106
Average (%) 93 94 95
1:8 Range (%) 88-104 93-101 94-103
Average (%) 93 93 94
1:16 Range (%) 94-99 91-100 91-103
Average (%) 95 94 95

Stability

The stability of Vedolizumab (Entyvio®) (mAb-based) is determined by the loss rate of activity. The loss rate of Vedolizumab (Entyvio®) (mAb-based) is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Item Specifications Storage
Micro ELISA Plate(Dismountable) 8 wells ×12 strips -20℃, 6 months
Reference Standard 2 vials
Concentrated Biotinylated Detection Ab (100×) 1 vial, 120 μL
Concentrated HRP Conjugate (100×) 1 vial, 120 μL -20℃(shading light), 6 months
Reference Standard & Sample Diluent 1 vial, 20 mL 4℃, 6 months
Biotinylated Detection Ab Diluent 1 vial, 14 mL
HRP Conjugate Diluent 1 vial, 14 mL
Concentrated Wash Buffer (25×) 1 vial, 30 mL
Substrate Reagent 1 vial, 10 mL 4℃(shading light)
Stop Solution 1 vial, 10 mL 4℃
Plate Sealer 5 pieces
Product Description 1 copy
Certificate of Analysis 1 copy

Other supplies required

Microplate reader with 450 nm wavelength filter
High-precision transfer pipette, EP tubes and disposable pipette tips
Incubator capable of maintaining 37℃
Deionized or distilled water
Absorbent paper
Loading slot for Wash Buffer

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

© Copyright 2021 TZYBIOTECH. All Rights Reserved. SiteMap